Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial.
Megumi OshimaBrendon L NeuenJingWei LiVlado PerkovicDavid M CharytanDick de ZeeuwRobert EdwardsTom GreeneAdeera LevinKenneth W MahaffeyLuca De NicolaCarol PollockNorman RosenthalDavid C WheelerMeg J JardineHiddo J L HeerspinkPublished in: Journal of the American Society of Nephrology : JASN (2020)
In people with type 2 diabetes and CKD, use of canagliflozin results in early, sustained reductions in albuminuria, which were independently associated with long-term kidney and cardiovascular outcomes.